CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx, Inc. has enrolled the first patient in its large-scale BENEFIT-HF trial, designed to evaluate the efficacy of its Barostim device in a significantly expanded heart failure population. The landmark randomized trial aims to enroll 2,500 patients across US and Germany centers, assessing all-cause mortality and heart failure decompensation events…